Clinofibrate

克利贝特

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameClinofibrate
Drug Alias Name双环苯氧酸clinofibratum环己双妥明斜纹祛脂乙酯Lipoclin +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPeroxisome proliferator-activated receptor α agonists
TargetsPeroxisome proliferator-activated receptor α
Therapy Area/IndicationsHyperlipidemias
Global Approved IndicationsHyperlipidemias
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date1981/01/01
Country/TerritoryMainland ChinaJapan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSumitomo Dainippon Pharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSumitomo DainipponTianjin Hankang Pharmaceutical & Biotechnology Company Ltd
Inactive CompaniesN/A
Active IndicationsHyperlipidemias
Inactive IndicationsN/A

Other Information

ATC CodeC10AB
Related LinksWikipediaDrugBankKEGG